Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression - PubMed (original) (raw)

Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression

M Pallis et al. Leukemia. 1997 Jul.

Abstract

The cells from approximately 70% patients with acute myeloblastic leukaemia exhibit autonomous growth characteristics in vitro, which have been associated with a poor response to therapy. We have previously shown that leukaemic cells with autonomous growth characteristics express high levels of bcl-2 and are relatively resistant to apoptosis. As bcl-x(L) is a bcl-2-related gene with anti-apoptotic activity which also confers resistance to cytotoxic drugs we have studied its expression in AML in relation to cellular growth characteristics and to the expression of P-glycoprotein. Cells from 15 patients were studied. Immunoblotting demonstrated bands at 31 kDa corresponding to bcl-x(L) from the cells of all patients. Bcl-x(S) was not detected in any sample. Using standardised, quantitative flow cytometry, bcl-x(L) expression ranged from 0.25 x 10(5) to 4.24 x 10(5) bound FITC molecules, (median 1.35 x 10[5]). AML blasts with autonomous growth in vitro expressed more bcl-x(L) (median 1.76 x 10[5]) than those which did not (median 0.86 x 10(5), P=0.01). Quantitative bcl-x(L) expression strongly correlated with that of P-glycoprotein, also measured by quantitative flow cytometry using the MRK16 antibody (r=0.95, P < 0.001), but not with MRPr1. These results provide a further explanation for the poor prognosis associated with autonomous in vitro growth of AML blasts and illustrate that these cells may coexpress different modalities of resistance to cytotoxic drug therapy involving both anti-apoptotic pathways (bcl-x(L), bcl-2) and classic multidrug resistance (MDR1). The implication of these findings is that the use of agents to reverse MDR1 function in AML may be unsuccessful in the absence of strategies to reduce resistance to apoptosis.

PubMed Disclaimer

Cited by

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.
Sillar JR, Enjeti AK. Sillar JR, et al. Cancers (Basel). 2019 Oct 26;11(11):1660. doi: 10.3390/cancers11111660. Cancers (Basel). 2019. PMID: 31717784 Free PMC article. Review.
The application of BH3 mimetics in myeloid leukemias.
Parry N, Wheadon H, Copland M. Parry N, et al. Cell Death Dis. 2021 Feb 26;12(2):222. doi: 10.1038/s41419-021-03500-6. Cell Death Dis. 2021. PMID: 33637708 Free PMC article. Review.
The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. Franke K, et al. Int J Nanomedicine. 2013;8:351-63. doi: 10.2147/IJN.S37465. Epub 2013 Jan 20. Int J Nanomedicine. 2013. PMID: 23378758 Free PMC article.
Application of CD45/SSC gating multiparameter flow cytometry in the classification of acute leukemia--an analysis of 139 cases.
Li W, Chen Z, Liu Z, Zou P. Li W, et al. J Tongji Med Univ. 2001;21(3):209-11. doi: 10.1007/BF02886431. J Tongji Med Univ. 2001. PMID: 12539578
The Association of _FLT3_-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients.
Notopuro PB, Nugraha J, Utomo B, Notopuro H. Notopuro PB, et al. Iran J Pathol. 2020 Fall;15(4):306-312. doi: 10.30699/ijp.2020.122579.2328. Epub 2020 Jul 16. Iran J Pathol. 2020. PMID: 32944043 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression - PubMed (original) (raw)